Hint mode is switched on Switch off

NervGen Pharma, ordinary share
NGEN, CA64082X2032

Add a stock to WL
Choose all Reset all
NervGen Pharma, сountry — Canada
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Issuer

Profile
NervGen Pharma Corporation offers solutions for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries, as well as provides research secondary applications such as multiple sclerosis, heart attack, stroke, and other neurodegenerative ...
NervGen Pharma Corporation offers solutions for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries, as well as provides research secondary applications such as multiple sclerosis, heart attack, stroke, and other neurodegenerative diseases.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    NervGen Pharma Corporation
  • Industry
    Pharmaceutical Preparation and Biotechnology

IFRS/US GAAP reports

2025
IV q eng

Related Stock indices

Indicators

Holders

Industry Leaders

Registration is required to get access.